Background
Polycystic ovary syndrome (PCOS) is an endocrine disease in which related to obesity, metabolic disorders and is considered as one of the main causes of infertility in women. This trial was investigated the effects of green cardamom on the expression of genes implicated in obesity and diabetes among obese women with PCOS.
Methods
One hundred ninety-four PCOS women were randomly divided two groups: intervention (n = 99; 3 g/day green cardamom) and control groups (n = 95). All of them were given low calorie diet. Anthropometric, glycemic and androgen hormones were assessed before and after 16-week intervention. The reverse transcription-polymerase chain reaction (RT-PCR) method was used to measure fat mass and obesity-associated (FTO), peroxisome proliferative activating receptor- (PPAR-), carnitine palmitoyltransferase 1A (CPT1A), acetyl-CoA carboxylase beta (ACAB), leptin receptor (LEPR), ghrelin, and lamin A/C (LAMIN) genes expression in each group.
Results
Anthropometric indices were significantly decreased after intervention in both two studied groups. Glycemic indices and androgen hormones were significantly improved in the intervention group compared to the control group. The expression levels of FTO, CPT1A, LEPR, and LAMIN were significantly downregulated compared to control group (P < 0.001), as well as, PPAR-y was significantly upregulated in the intervention group after intervention with green cardamom compared to control group (P < 0.001).
Conclusion
This current study showed that the administration of green cardamom is a beneficial approach for improving anthropometric, glycemic, and androgen hormones, as well as obesity and diabetes genes expression in PCOS women under the low-calorie diet.
Trial registration
This trial was registered with the Iranian Clinical Trials Registry (registration number: IRCT20200608047697N1). 1 August, 2020; https://www.irct.ir/trial/48748
BackgroundPolycystic ovary syndrome (PCOS) is an endocrine disease in which related obesity, metabolic disorders and is considered as one of the main causes of infertility in women. This trial was investigated the effects of green cardamom on obesity and diabetes genes expression among obese women with PCOS.Methods194 PCOS women were randomly divided two groups: intervention (n= 99; 3 g/day green cardamom) and control groups (n=95). All of them were given low calorie diet. Anthropometric, glycemic and androgen hormones were assessed before and after 16 weeks’ intervention. Fat mass and obesity-associated (FTO), Peroxisome proliferative activating Receptor-γ (PPAR-γ) Carnitine Palmitoyltransferase 1A (CPT1A), Acetyl-CoA Carboxylase Beta (ACAB), Leptin Receptor (LEPR), Gherlin, and lamin A/C (LAMIN) genes in PBMC were measured in each group using reverse transcription-polymerase chain reaction (RT-PCR) method.ResultsAnthropometric indices were significantly decreased after intervention in both two studied groups. Glycemic indices and androgen hormones were significantly improved in the intervention group. The expression level of FTO, CPT1A, LEPR, and LAMIN were significantly down-regulated (P<0.001), as well as, PPAR-y was significantly up-regulated in the intervention group after intervention with green cardamom (P<0.001). ConclusionThis current study showed that the administration of green cardamom is a beneficial approach for improving of anthropometric, glycemic and androgen hormones, as well as, obesity and diabetes genes expression in PCOS women under low calorie diet. This trial was registered with the Iranian Clinical Trials Registry (registration number: IRCT20200608047697N1). 1 August, 2020; https://www.irct.ir/trial/48748
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.